Martino S, Decker D A, Hynes H E, Kresge C L
Wayne State University, School of Medicine, Division of Medical Oncology, Detroit, Michigan.
Invest New Drugs. 1987 Dec;5(4):373-4. doi: 10.1007/BF00169977.
Sixteen women with advanced epithelial ovarian carcinoma were treated with Aclacinomycin-A 40 mg/M2 given as a weekly infusion for four consecutive weeks followed by a two week rest period. All had failed prior chemotherapy. No responses were observed. Nausea and vomiting were the most frequent side effect. Myelosuppression was minimal. This dose and schedule of Aclacinomycin-A are not recommended for further trials in ovarian carcinoma.
16名晚期上皮性卵巢癌女性患者接受了阿克拉霉素-A治疗，剂量为40mg/M²，每周静脉输注一次，连续四周，随后休息两周。所有患者之前的化疗均失败。未观察到任何反应。恶心和呕吐是最常见的副作用。骨髓抑制作用轻微。不建议将此剂量和疗程的阿克拉霉素-A用于卵巢癌的进一步试验。
